FDA and EMA Discussed Botanical Drug Pathways
Regulators met in Amsterdam to explore ways to streamline the approval process for botanical drug products.
Updated on Sept. 25, 2026 in Botany
Live Poll
Should government agencies simplify approval processes to make new herbal or botanical drugs more accessible?
The FDA and the European Medicines Agency held a meeting in Amsterdam to discuss regulatory pathways for botanical drugs. Over 1,000 attendees participated in the discussion, which explored potential changes to simplify market access for these substances.
Why it matters
The meeting aimed to address the stark differences in regulatory requirements that make bringing botanical drugs to market difficult. Simplifying these processes could potentially reduce the high costs and failure rates currently associated with U.S. botanical drug development.
The FDA requires rigorous proof of manufacturing consistency and limits on batch-to-batch variation, while the EU allows reliance on historical safety data. U.S. approval processes currently cost up to 10 times more than those in the European Union.
The players
Food and Drug Administration
The FDA is a U.S. federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
European Medicines Agency
The EMA is an agency of the European Union in charge of the evaluation and supervision of pharmaceutical products for use in the EU.
The details
The FDA uses the Food, Drug and Cosmetic Act to regulate botanical drugs, a framework that has resulted in only four approvals over several decades. Many U.S. submissions fail specifically because they struggle to meet the strict quality parameters required to demonstrate consistency in complex botanical substances.
Timeline
The meeting between the FDA and EMA took place on September 25, 2026.
The Big Picture
This meeting highlights a paradigm shift in global botanical drug research as agencies seek to harmonize standards set by the Food, Drug and Cosmetic Act. By comparing these rigid U.S. requirements against European safety-data approaches, researchers hope to unlock new development pathways.
Streamlined approval processes could lead to an increased variety of botanical drugs reaching the U.S. market. This change may eventually provide patients with more standardized, FDA-approved treatment options derived from natural substances.
The takeaway
Regulators are actively working to bridge the gap between U.S. and EU standards to lower the barrier for botanical drug development. Researchers and developers should watch for future guidance that may prioritize manufacturing consistency metrics over traditional herbal data.
What happens next
Organizers have announced that a recording of the meeting will be made available to the public in the near future.
Further reading
Explore more developments in the field of Botany.
Live Poll
Should government agencies simplify approval processes to make new herbal or botanical drugs more accessible?
